Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs will be updated March 1, 2024:
Effective April 1, 2024:
- Reblozyl
- Rapid to Intermediate Acting Insulin
- Lysosomal Storage Disorders
- Substrate Reduction Therapy
- Daybue
- Copay Waiver
- SA Oncology
- Oxybate
- Wakix
- Sunosi
- Urea Cycle Disorders
- Synagis
- Vascepa
- Antifungals
- Pseudobulbar Affect
- Acute Hepatic Porphyria
- Oxlumo
- Xdemvy
- Zilbrysq
- Syfovre (MRx)
Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.
To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization.
If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.